Literature DB >> 33425279

Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19.

Mohammad Bagherzade1, Mahmoud Parham1, Somayeh Zohali2, Sedighe Molaei2, Jamshid Vafaeimanesh1,3.   

Abstract

BACKGROUND: COVID-19 pandemic is a global concern. Unfortunately, there is no exclusive treatment for critical patients to survive. In this study, we suggest using a novel three-dimensional treatment mainly based upon immune system modulation to fix the virus chaos, through cytokine storm as the main character of COVID-19 infection scenario. CASE
PRESENTATION: A young man infected by SARS-CoV-2 who suffered from respiratory arrest and loss of consciousness, underwent cardiopulmonary resuscitation and endotracheal intubation. Following ICU administration and confirmed diagnosis of COVID-19, considering critical condition of the young patient, plasmapheresis was performed once on a daily basis, three doses of interferon beta(IFN-β-1b) was injected subcutaneously every other day and dexamethasone was given at a dose of 4 mg every 8 hours along with common antiviral regimen. After 2 days, the patient was extubated and transferred from the ICU to the ward where plasmapheresis was performed 4 times daily for 4 days. Finally, after 7 days of hospitalization, the patient was discharged with a good general condition.
CONCLUSION: We modulated the immune system through plasmapheresis to sweep out the released cytokines. Also, corticosteroid along with interferon was added to common antiviral treatments. Our data suggest that this combined method is effective for critically ill COVID-19 patients.

Entities:  

Keywords:  COVID-19; corticosteroid therapy; interferon; therapeutic plasma exchange

Year:  2020        PMID: 33425279      PMCID: PMC7780874          DOI: 10.22088/cjim.11.0.572

Source DB:  PubMed          Journal:  Caspian J Intern Med        ISSN: 2008-6164


  24 in total

1.  Drug treatment options for the 2019-new coronavirus (2019-nCoV).

Authors:  Hongzhou Lu
Journal:  Biosci Trends       Date:  2020-01-28       Impact factor: 2.400

2.  Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis.

Authors:  Natalia Lubina-Dąbrowska; Adam Stepień; Grzegorz Sulkowski; Beata Dąbrowska-Bouta; Józef Langfort; Małgorzata Chalimoniuk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-03-15       Impact factor: 4.291

3.  Adjuvant corticosteroid therapy for critically ill patients with COVID-19.

Authors:  Xiaofan Lu; Taige Chen; Yang Wang; Jun Wang; Fangrong Yan
Journal:  Crit Care       Date:  2020-05-19       Impact factor: 9.097

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study.

Authors:  Tung Wai Auyeung; Jenny S W Lee; Wing Kin Lai; Chun Hung Choi; Hoi Kan Lee; Joo Shim Lee; Po Chun Li; Ka Ho Lok; Yuk Yung Ng; Wai Ming Wong; Yiu Ming Yeung
Journal:  J Infect       Date:  2005-08       Impact factor: 6.072

6.  The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.

Authors:  Jaegyun Lim; Seunghyun Jeon; Hyun Young Shin; Moon Jung Kim; Yu Min Seong; Wang Jun Lee; Kang Won Choe; Yu Min Kang; Baeckseung Lee; Sang Joon Park
Journal:  J Korean Med Sci       Date:  2020-02-24       Impact factor: 2.153

Review 7.  COVID-19: Melatonin as a potential adjuvant treatment.

Authors:  Rui Zhang; Xuebin Wang; Leng Ni; Xiao Di; Baitao Ma; Shuai Niu; Changwei Liu; Russel J Reiter
Journal:  Life Sci       Date:  2020-03-23       Impact factor: 5.037

8.  A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.

Authors:  Philip Keith; Matthew Day; Linda Perkins; Lou Moyer; Kristi Hewitt; Adam Wells
Journal:  Crit Care       Date:  2020-04-02       Impact factor: 9.097

9.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients.

Authors:  Meijuan Zheng; Yong Gao; Gang Wang; Guobin Song; Siyu Liu; Dandan Sun; Yuanhong Xu; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

10.  IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?

Authors:  Shubham Atal; Zeenat Fatima
Journal:  Pharmaceut Med       Date:  2020-08
View more
  2 in total

1.  Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings.

Authors:  Vincenza Granata; Roberta Fusco; Sergio Venanzio Setola; Roberta Galdiero; Carmine Picone; Francesco Izzo; Roberta D'Aniello; Vittorio Miele; Roberta Grassi; Roberto Grassi; Antonella Petrillo
Journal:  Biology (Basel)       Date:  2021-03-11

2.  Therapeutic plasma exchange: A potential therapeutic modality for critically ill adults with severe acute respiratory syndrome coronavirus 2 infection.

Authors:  Sabria Al-Hashami; Faryal Khamis; Maha Al-Yahyay; Samata Al-Dowaiki; Louza Al-Mashaykhi; Huda Al-Khalili; Juhi Chandwani; Issa Al-Salmi; Ibrahim Al-Zakwani
Journal:  J Clin Apher       Date:  2022-09-14       Impact factor: 2.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.